Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Patient #16, #17 & #18

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Jul 06, 2021 3:59pm

174 Views

Post# 33500268

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Patient #16, #17 & #18

Hey Hey! 100-110? Even better Cr %s numbers. ;-) Yeah Halt isn't the right word as the Phase 2 would transition to commercialization. Where insurance companies would then be paying for the study, along with TLT, instead of TLT paying for all of it.

Eoganacht wrote: I don't think they will halt the trial until they treat all 100-110 patients. If they get accelerated approval from the FDA one of the conditions of approval would likely be finishing the trial.

Rumpl3StiltSkin wrote: I'm guessing they'll keep treating patients in the US and Canada until they get these efficacy %s up where they want them, then they can halt phase 2. Around 40 or so patients? :-)

enriquesuave wrote:
Even if they get 5 on 8 that would be great plus the 2 from PH1, that would be like 7 out 10 patients who got optimized procedure. That would confirm a high efficacy for the market to understand what's going on here. All IMHO

StevenBirch wrote: Don't you guys think we should wait for the next update, less than a month, before assuming that no more US patients have been treated? I understand the frustration but it is obvious now that the AGM was not going to reveal anything that we didn't already know.

Besides, and maybe I missed it previously but I thought they needed a minimum of 25 treated and now it seems like 20 - 25 so we are already there. Now only 8 have been treated with the optimized procedure but what if they go 7 for 8? Finding that out isn't that far away.

It can be depressing seeing the frustration here but isn't there something between $0.25 and an eventual buyout? Shouldn't we see a significant bounce within weeks or months if the results are what we expect?